Gracell Biotechnologies, a Nasdaq-listed Chinese biopharmaceutical firm that develops cell therapies targeting cancer and autoimmune diseases, has inked a deal to raise $150 million in a private placement from a group of healthcare specialist funds.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
